SEC Filings
Corbus Reports No Serious Psychiatric Events In Early Obesity-Pill Trial
Adverse events caused 12.9% of the highest-dose group to stop treatment; previously reported weight loss averaged 5% at 12 weeks.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
SEC Filings
Adverse events caused 12.9% of the highest-dose group to stop treatment; previously reported weight loss averaged 5% at 12 weeks.
SEC Filings
Breast-cancer trial results are expected in the second half of 2027; an earlier solid-tumor readout is due in December.
SEC Filings
The kidney-drug company can request another $80 million, but lenders decide whether to provide it.
Deals
The target's shareholders would receive 0.6279 Ameris shares per share, with closing expected in the first quarter of 2027.
SEC Filings
Joseph E. Creed will serve on the retailer's audit and strategic planning and finance committees.
Earnings
Beef losses deepened and chicken profit fell, while prepared foods earned more and Tyson increased its dividend.
SEC Filings
Jorey retained a 2.7% stake as the treatment-system company sought fresh capital and relief from loan requirements.
Earnings
Lower content costs and growing ad sales helped the streaming business, but membership revenue fell 6%.
Earnings
Manufacturing spending fell as Larimar increased commercial preparations for nomlabofusp, its experimental Friedreich’s ataxia treatment.
SEC Filings
Baxfendy could become the EU's first aldosterone synthase inhibitor for patients whose blood pressure remains uncontrolled on other medicines.
SEC Filings
Initial breast-cancer clinical data are expected in the second half of 2027, with research spending lower after earlier cuts.
SEC Filings
PEMGARDA sales rose 18%, but its emergency authorization is due to end in mid-2027.